Please ensure Javascript is enabled for purposes of website accessibility

Pfizer's CEO Makes a Prediction That Could Mean Huge Post-Pandemic Success

By Prosper Junior Bakiny - May 8, 2021 at 6:20AM

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

Strong growth in revenue and earnings wasn't the only story in the company's latest quarterly update.

On May 4, pharma giant Pfizer (PFE -1.35%) released its financial results for the first quarter ending March 31. As expected, its coronavirus vaccine, BNT162b2, was the star of the quarter. Pfizer recorded $3.5 billion in sales from BNT162b2, which it developed in collaboration with Germany-based BioNTech SE (BNTX 1.14%). The vaccine obviously helped boost Pfizer's performance in the first quarter, and that will continue for the duration of the pandemic.

However, during the company's first-quarter earnings conference call transcript, Pfizer's CEO Albert Bourla made a prediction you will definitely want to hear.

Young man wearing a mask receives vaccine from a mature physician wearing a face shield and a mask.

Image source: Getty Images

Could COVID-19 become the new flu?

Right now, governments worldwide are primarily concerned with ending the COVID-19 pandemic. That's why Pfizer and BioNTech -- as well as other companies that have developed vaccines for the disease -- have signed agreements to deliver hundreds of million doses of their respective products.

But COVID-19 won't simply disappear once the outbreak is under control. And according to Albert Bourla, neither will the need for vaccines. In his own words: "Based on what we have seen, we believe that a durable demand from our COVID-19 vaccine, similar to that of the flu vaccines, is a likely outcome."

If this prediction proves accurate, Pfizer could continue to profit from sales of BNT162b2 for many years to come. What does this mean for investors?

The future of the coronavirus vaccine market

Of course, Pfizer has to compete with several of its peers in the coronavirus vaccine market. And while the company's BNT162b2 proved highly effective in a phase 3 clinical trial, newer variants of the SARS-CoV-2 virus that causes COVID-19 could complicate things. But these potential headwinds are unlikely to totally take the wind out of Pfizer's sails.

Despite the competition, the drugmaker expects to generate $26 billion in sales from BNT162b2 this year. The company also has supply agreements in place that stretch to at least 2023. In other words, Pfizer is in a good position to continue generating decent revenue from this blockbuster product for at least the next couple of years.

The company also thinks its BNT162b2 is very effective against all the current variants of SARS-CoV-2. Pfizer has other coronavirus vaccine candidates in its pipeline to deal with future variants or mutations, including those that could vaccinate children as young as two. The company should be ready to tackle any variants that emerge in a regulatory process of 100 days, if needed. All things considered, the pharma giant seems to have most bases covered.

But there's more

Pfizer looks likely to remain a leader in the COVID-19 vaccine market, but there are more reasons to consider purchasing shares of the company. During the first quarter, the company reported $14.6 billion in revenue, a 42% increase compared to last year's first quarter. Excluding sales from BNT162b2, the company's sales grew by 8%.

Importantly, Pfizer spun off its off-patent medicine unit Upjohn to the company formerly known as Mylan last year. The new entity, called Viatris, made its debut on the stock market on Nov. 17. Upjohn has been severely limiting Pfizer's revenue and earnings growth as several of its products continuously posted declining sales. Thanks to this transaction, Pfizer is now hyperfocused on its biopharma business, which has been performing pretty well all along.

The company boasts at least a couple more blockbuster drugs (aside from BNT162b2), and Pfizer is running well over two dozen clinical trials. Pfizer can continue adding more drugs (and vaccines) to its lineup, thereby broadening its sources of revenue. What's more, the market continues to undervalue Pfizer. The company is currently trading at just 10.7 times forward earnings, while its price-to-earnings growth ratio (PEG) is 0.9. (For context, the average S&P 500 forward price-to-earnings ratio is about 22, and a PEG below 1 suggests a company is undervalued.) Moreover, Pfizer boasts a dividend yield of 3.9% -- compared to 1.3% for the S&P 500.

On the whole, there are more than enough reasons to seriously consider adding shares of this healthcare stock to your portfolio.

Prosper Junior Bakiny has no position in any of the stocks mentioned. The Motley Fool recommends Viatris Inc. The Motley Fool has a disclosure policy.

Invest Smarter with The Motley Fool

Join Over 1 Million Premium Members Receiving…

  • New Stock Picks Each Month
  • Detailed Analysis of Companies
  • Model Portfolios
  • Live Streaming During Market Hours
  • And Much More
Get Started Now

Stocks Mentioned

Pfizer Inc. Stock Quote
Pfizer Inc.
$49.44 (-1.35%) $0.68
BioNTech SE Stock Quote
BioNTech SE
$162.18 (1.14%) $1.83

*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.

Related Articles

Motley Fool Returns

Motley Fool Stock Advisor

Market-beating stocks from our award-winning analyst team.

Stock Advisor Returns
S&P 500 Returns

Calculated by average return of all stock recommendations since inception of the Stock Advisor service in February of 2002. Returns as of 08/15/2022.

Discounted offers are only available to new members. Stock Advisor list price is $199 per year.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.